Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration

Inflamm Res. 1999 Dec:48 Suppl 2:S130-1. doi: 10.1007/s000110050552.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Benzene Derivatives / pharmacology*
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology*
  • Dinoprostone / biosynthesis
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Furans / pharmacology*
  • Humans
  • Isoenzymes / drug effects*
  • Lipopolysaccharides / pharmacology
  • Male
  • Membrane Proteins
  • Prostaglandin-Endoperoxide Synthases / drug effects*

Substances

  • 3-2(-propyloxy)-(4-methylsulfonylphenyl)-(5,5-dimethyl)furanone
  • Anti-Inflammatory Agents, Non-Steroidal
  • Benzene Derivatives
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Furans
  • Isoenzymes
  • Lipopolysaccharides
  • Membrane Proteins
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Dinoprostone